XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaboration and Other Agreements - Zai Lab (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 27 Months Ended
Jun. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Mar. 31, 2019
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Dec. 31, 2021
Jun. 15, 2021
Mar. 31, 2021
Collaboration And Other Agreements [Line Items]                    
Revenues   $ 41,734 $ 15,662   $ 78,842 $ 63,300        
Common stock, par value (in dollars per share)   $ 0.01     $ 0.01   $ 0.01 $ 0.01    
Deferred revenue, current   $ 7,085     $ 7,085   $ 7,085 $ 20,646    
Deferred revenue, net of current portion   5,084     5,084   5,084 0    
2018 Zai Lab Agreement | Zai Labs                    
Collaboration And Other Agreements [Line Items]                    
Non-refundable upfront payment       $ 25,000            
Non-refundable upfront payment, net of tax withholding       22,500            
Nonrefundable payment tax withholding       $ 2,500            
Potential development and regulatory milestone payments under agreement                   $ 140,000
Development and regulatory milestones recognized             9,000      
Revenues   0 0   4,900 0        
Milestones Value Added Tax             8,100      
Zai Lab Agreement, Margetuximab | Zai Labs | Maximum                    
Collaboration And Other Agreements [Line Items]                    
Potential proceeds from royalties (percent)       20.00%            
Zai Lab Agreement, TRIDENT molecule | Zai Labs                    
Collaboration And Other Agreements [Line Items]                    
Potential proceeds from royalties (percent)       10.00%            
Zai Lab Clinical Supply Agreements | Zai Labs                    
Collaboration And Other Agreements [Line Items]                    
Revenues   0 600   300 2,300        
2021 Zai Lab Agreements | Zai Labs                    
Collaboration And Other Agreements [Line Items]                    
Non-refundable upfront payment $ 25,000                  
Potential development and regulatory milestone payments under agreement                 $ 680,000  
Deferred revenue   0     0   $ 0 $ 16,100    
Revenues   $ 1,800 $ 3,700   $ 16,800 $ 18,100        
Proceeds of stock sale 30,000                  
Sales of stock purchase price (in dollars per share)                 $ 31.3  
Potential commercial milestone payments under agreement                 $ 600,000  
Collaborative agreement transaction price                 $ 40,400  
Variable consideration recognized 5,000                  
2021 Zai Lab Agreements | Zai Labs | Additional Paid-In Capital                    
Collaboration And Other Agreements [Line Items]                    
Premium received on stock purchase $ 10,400